AML

Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute

Retrieved on: 
Wednesday, October 19, 2022
News, U.S. Securities and Exchange Commission, Pancreatic cancer, HRAS, G4S, Colon cancer staging, Growth, Acute myeloid leukemia, AML, NRAS, Family, Neoplasm, Security (finance), Risk, RAS, Orphan drug, KRAS, Private Securities Litigation Reform Act, Form 10-K, Company, National Cancer Institute, Adult, Patent, Prostate cancer, Protein, National, Fast Track, Clinical trial, Lung cancer, Death, FDA, Cancer, Pharmaceutical industry

CARLSBAD, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces the presentation of two posters detailing the Company’s RAS-Targeted platform at the National Cancer Institute-sponsored Fourth RAS Initiative Symposium to be held October 17-19, 2022 at The Advanced Technology Research Facility of the National Cancer Institute in Frederick, Maryland.

Key Points: 
  • Following screening to identify an initial candidate inhibitor against pancreatic cancer tumor growth, investigators analyzed in vitro and in vivo activity against these tumors.
  • It also suppressed xenograft development of human and mouse RAS-driven pancreatic tumor cell lines and reduced the growth of pancreatic cancer patient-derived xenograft models.
  • The study also showed that RAS-F enhanced the effects of immune checkpoint therapy in syngeneic tumor xenografts.
  • For example, mutant KRAS is found in 98% of pancreatic ductal adenocarcinomas, 52% of colon cancers, and 32% of lung adenocarcinomas.

Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on Tuesday, November 1, 2022

Retrieved on: 
Tuesday, October 18, 2022
Toxic leukoencephalopathy, MDS, Company, Lymphatic system, Patient, Hematology, Investor relations, Webcast, Mission statement, PIN, EDGAR, Acute myeloid leukemia, Q&A, Call Me, AML, SEDAR, Pharmaceutical industry

They also will have the option to take advantage of a new Call Me button and the system will automatically dial out to connect to the Q&A session.

Key Points: 
  • They also will have the option to take advantage of a new Call Me button and the system will automatically dial out to connect to the Q&A session.
  • The audio webcast can also be accessed through a link on the Investor Relations section of Aptoses website here .
  • The press release, the financial statements and the managements discussion and analysis for the quarter ended September 30, 2022 will be available on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml.
  • Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology.

Hillstream’s New Anti-Cancer Mechanism Quatramer-based Ferroptosis Inducer, HSB-1216 Abstract Available for Viewing at EORTC-NCI-AACR Symposium

Retrieved on: 
Tuesday, October 18, 2022
Leukemia, Acute myeloid leukemia, IND, AML, Cytokine, Neoplasm, ENA, Biotechnology, Patient, Decitabine, LSCS, Rupture, Tumor microenvironment, Cell death, Toxicity, CEO, Prognosis, Iron, GLOBE, IMCD, Stem cell, Peptide, FDA, Poster, NCI, Ferroptosis, Pharmaceutical industry, Vaccine, Hillstream loach

Unfortunately, despite recent advances in the treatment, the prognosis is poor for almost all older adults and half of patients under age 60.

Key Points: 
  • Unfortunately, despite recent advances in the treatment, the prognosis is poor for almost all older adults and half of patients under age 60.
  • Leukemic stem cells (LSCs) represent a subset of the leukemic cell population contributing to leukemia relapse and are relatively refractory to conventional treatments.
  • HSB-1216 treatment resulted in growth inhibition and induction of cell death of multiple AML cell lines.
  • HSB-1216 is a novel and potent inducer of an emerging mechanism of cell death called ferroptosis.

Qualigen Therapeutics to Present at LD Micro Main Event XV

Retrieved on: 
Tuesday, October 18, 2022
News, U.S. Securities and Exchange Commission, G4S, Therapy, Acute myeloid leukemia, AML, Security (finance), Risk, RAS, Orphan drug, Private Securities Litigation Reform Act, Form 10-K, Company, Adult, Patent, Prostate cancer, Protein, Fast Track, Clinical trial, Lung cancer, FDA, Cancer, Pharmaceutical industry

The online livestream can be viewed by going to https://me22.mysequire.com/ , and clicking on Qualigen Therapeutics within the schedule.

Key Points: 
  • The online livestream can be viewed by going to https://me22.mysequire.com/ , and clicking on Qualigen Therapeutics within the schedule.
  • For more information about Qualigen Therapeutics, Inc., please visit www.qualigeninc.com .
  • This news release contains forward-looking statements by Qualigen that involve risks and uncertainties and reflect the Company's judgment as of the date of this release.
  • This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Global Acute Myeloid Leukemia Therapeutics Market Report (2022 to 2027) - Improved Immunotoxins, Alkylating Agents, Monoclonal Antibodies and Multidrug-Resistant Modulators is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, October 21, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Adoption, Globe, Acute myeloid leukemia, Leukemia, Weight loss, Therapy, Fatigue, Transplant, Prevalence, Growth, AML, Nosebleed, Research, Bone marrow, R, Immunotoxin, Immune system, Disorder, Industry, Awareness, Skin, White blood cell, COVID-19, Pharmaceutical industry, Vaccine

The increasing prevalence of leukemia across the globe represents one of the key factors driving the growth of the market.

Key Points: 
  • The increasing prevalence of leukemia across the globe represents one of the key factors driving the growth of the market.
  • What has been the impact of COVID-19 on the global acute myeloid leukemia therapeutics market?
  • What is the structure of the global acute myeloid leukemia therapeutics market and who are the key players?
  • The publisher provides an analysis of the key trends in each sub-segment of the global acute myeloid leukemia therapeutics market report, along with forecasts at the global, regional and country level from 2022-2027.

Helix and BM Technologies Collaborate to Deliver Next-Generation Embedded Finance

Retrieved on: 
Thursday, October 20, 2022
Professional Services, Technology, Finance, Software, Fintech, Banking, AML, Jay Sidhu, Education, KYC, NYSE, Program, Technology, Goal, Mobile backend as a service, BM, Solution, Compliance, Online shopping, Helix

Helix by Q2 (NYSE:QTWO), a cloud-native platform purpose-built for embedded finance, and BM Technologies, Inc. (NYSE American:BMTX), formerly known as BankMobile, have announced they are partnering to provide comprehensive embedded banking solutions for consumer brands, combining Helixs embedded finance platform and bank partnerships with BM Technologies award-winning app development services and program management.

Key Points: 
  • Helix by Q2 (NYSE:QTWO), a cloud-native platform purpose-built for embedded finance, and BM Technologies, Inc. (NYSE American:BMTX), formerly known as BankMobile, have announced they are partnering to provide comprehensive embedded banking solutions for consumer brands, combining Helixs embedded finance platform and bank partnerships with BM Technologies award-winning app development services and program management.
  • BM Technologies offers a completely customizable presentation experience and industry-leading back-office capabilities as a part of its Banking-as-a-Service (BaaS) product offering on a cloud-based platform built for embedded finance.
  • We are excited to work together with BM Technologies to meet a clear need in the market.
  • In addition, our complementary solutions will be a win-win for everyone involved, said Jamie Donahue, chief technology officer at BM Technologies.

Binance Custody Ensures Institutional Compliance with TRM Labs Integration

Retrieved on: 
Thursday, October 20, 2022
Technology, Finance, Security, Professional Services, Business, Software, Blockchain, Networks, Data Management, Cryptocurrency, Adoption, Risk management, ISO, Trust, Nationwide Asset Services, VASP, Risk assessment, EVP, SOC, AML, Intelligence, Â, TRM, Technology, ISO 27001, Industry, Blockchain, Safety, MPC, KYT, Solution, Compliance, Custody, Bank, Cryptocurrency, Binance

Binance Custody, an institutional-grade digital asset custody solution, has onboarded risk management tools from TRM Labs, the industry leader in blockchain analytics and intelligence technology.

Key Points: 
  • Binance Custody, an institutional-grade digital asset custody solution, has onboarded risk management tools from TRM Labs, the industry leader in blockchain analytics and intelligence technology.
  • The integration enables Binance Custody to ensure its regulatory compliance and risk management program for client holdings through TRMs full-service platform.
  • As an institutional custodian, our utmost priority is to provide secure and compliant services that our clients can trust, said Athena Yu, EVP of Binance Custody.
  • Its seamless integration with the Binance ecosystem also provides an additional layer of deep liquidity venues and institutional services.

Unit21 Launches Fintech Fraud DAO to Combat Financial Crime With Brex, Chime and PrimeTrust as Early Customers

Retrieved on: 
Wednesday, October 19, 2022
Professional Services, Security, Technology, Cryptocurrency, Software, Finance, Fintech, Risk, AML, KYC, Organization, Compliance, ROI, DAO, Air base, Science and technology in Asia, Industry, Â, Ecosystem, Early warning, Brex, Fraud, Cryptocurrency, Online shopping, Audit, Financial technology

For every participant, the Fintech Fraud DAO connects risk and compliance infrastructure to their end users data, by allowing participants to privately and securely contribute anonymized transactional behavior.

Key Points: 
  • For every participant, the Fintech Fraud DAO connects risk and compliance infrastructure to their end users data, by allowing participants to privately and securely contribute anonymized transactional behavior.
  • Each participating fintech has governing authority over the DAO, through the distribution of governance tokens in the DAO network.
  • As the fintech industry continues to grow, so do the myriad of risks facing industry organizations, said Clarence Chio, President, Fintech Fraud DAO.
  • The Fintech Fraud DAO is owned and operated by Unit21 , a data infrastructure company at the forefront of the no-code enterprise revolution.

Diebold Nixdorf Partners with Featurespace to Provide Fraud Prevention Technology Within its Payments Processing Platform

Retrieved on: 
Friday, October 21, 2022
API, NatWest, Risk, Global Banking & Finance Review, AML, NYSE, Partnership, Technology, Diebold Nixdorf, DBD, CEO, Permanent, PDT, HSBC, Fraud, Danske Bank, TSYS, Cryptocurrency, Online shopping, Incorporated, Akbank

CAMBRIDGE, England and HUDSON, Ohio, Oct. 21, 2022 /PRNewswire/ -- Diebold Nixdorf (NYSE: DBD), a world leader in automating, digitizing and transforming the way people bank and shop, and Featurespace, a world leader in enterprise financial crime prevention, today announced that the companies are partnering to integrate its highly specialized, fraud prevention technology into Diebold Nixdorf's Vynamic® Payments platform.

Key Points: 
  • By partnering with Featurespace, Diebold Nixdorf can provide financial institutions a fully integrated payments solution with proven real-time fraud detection and prevention capabilities without the concern of managing multiple vendors.
  • Joe Myers, executive vice president, Global Banking, at Diebold Nixdorf said:"We are excited to begin this partnership with Featurespace as the technology and product features of ARIC Risk Hub perfectly align with Diebold Nixdorf's payments transaction processing.
  • By integrating the holistic solution into our Vynamic Payments platform, we can provide financial institutions with the most powerful and open technology to combat fraud and financial crime."
  • Fraud Prevention & AML in Payments as a Service , with Dave Excell, Founder, Featurespace, Tuesday 25 October, 1:00pm PDT
    Featurespace is the world leader in enterprise grade technology that prevents fraud and financial crime.

Voyager Labs Announces Relocation to U.S. to Support Accelerated Growth

Retrieved on: 
Wednesday, October 19, 2022
Terrorism, Growth, Machine learning, AML, Organization, Bromley, Contract, Artificial intelligence, Technology, Company, Narcotic, CEO, Federation, Fortune 500, Inc., Leadership, Shipbuilding, Drug, Courtney

NEW YORK, Oct. 19, 2022 /PRNewswire/ -- Voyager Labs, an award-winning world leader in advanced investigation solutions, announced that it is moving its headquarters from Israel to the United States to advance the operations and growth of the company. Courtney Bromley, who joined Voyager Labs in March 2022 to lead the U.S. business, will now oversee all global staff and operations as CEO of Voyager Labs, Inc.

Key Points: 
  • Courtney Bromley, who joined Voyager Labs in March 2022 to lead the U.S. business, will now oversee all global staff and operations as CEO of Voyager Labs, Inc.
    "We are excited to launch the next phase of our growth strategy with this relocation and change in global leadership," saidAvi Korenblum, Founder and former CEO of Voyager Labs.
  • "Moving our business operations to the U.S. positions Voyager Labs to better serve our fastest-growing markets which include the U.S. federal government as well as state and local law enforcement and prosecution agencies."
  • Under Bromley, Voyager Labs' U.S. business is on-pace for record growth in new contracts as well as achieving 100% customer renewals this year.
  • "Thanks to Avi's leadership, Voyager Labs is well positioned for rapid growth," said Bromley.